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EXPERIMENTAL DETAILS 
Melting points were determined on a Boetius PMHK apparatus and were not corrected. 
IR spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal.  
NMR: 1H and 13C NMR spectra were recorded on a Varian Gemini-200 spectrometer (at 200 
and 50 MHz, respectively) and/or a Bruker Ultrashield Advance III spectrometer (at 500 and 
125 MHz, respectively) in the indicated solvent using TMS as the internal standard. Chemical 
shifts are expressed in ppm (δ) values and coupling constants (J) in Hz.  The elemental 
analysis was performed on the Vario EL III – C, H, N, S/O elemental analyzer (Elementar 
Analysensysteme GmbH, Hanau, Germany). ESI MS spectra of the synthesized compounds 
were recorded on an Agilent Technologies 6210 Time-of-Flight LC/MS instrument in positive 
ion mode using CH3CN/H2O = 1/1 with 0.2 % HCOOH as the carrying solvent solution.  The 
samples were dissolved in pure acetonitrile (HPLC grade).  The selected values were as 
follows: capillary voltage = 4 kV; gas temperature = 350 °C; drying gas = 12.l min-1; 
nebulizer pressure = 45 psig; fragmentor voltage =70 V. Compounds were analyzed for purity 
using Waters 1525 HPLC dual pump system equipped with an Alltech Select degasser system, 
and a dual λ 2487 UV-VIS detector, and Agilent 1200 HPLC system equipped with Quat 
Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 (G1316A) and Detector 1260 
DAD VL+(G1315C). All analyzed compounds were >95 % pure. HPLC analysis was per-
formed in two diverse systems for each analyzed compound. Compounds were dissolved in 
methanol, final concentrations were ~ 1 mg/mL. Applied HPLC methods were as follows: 
Method A: Zorbax Eclipse Plus C18 2.1 × 100 mm, 1.8µ, S.N.USUXU04444 was used 
as the stationary phase. Eluent was made of the following solvents: 0.2 % formic acid in water 
(A) and acetonitrile (B). The analysis were performed at 330 nm for compounds 14 and 17, 
and at 320 nm for compounds 15 and 16. Flow rate was 0.5 mL/min.  
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Compounds 14-17 were eluted using gradient protocol: 0–1 min 95 % A, 1–2 min 95 % 
A → 5 % A, 2–10 min 5 % A, 10–11 min 5 % A → 95 % A, 11–13 min 95 % A. 
Method B: Zorbax Eclipse Plus C18 2.1 × 100 mm, 1.8µ, S.N.USUXU04444 was used 
as the stationary phase. Eluent was made of the following solvents: 0.2 % formic acid in water 
(A) and methanol (B). The analysis were performed at 330 nm for compounds 14 and 17, and 
at 320 nm for compounds 15 and 16. Flow rate was 0.2 mL/min.  
Compounds 14-17 were eluted using gradient protocol: 0–1 min 95 % A, 1–2 min 95 % 
A → 5 % A, 2–10 min 5 % A, 10–11 min 5 % A → 95 % A, 11–13 min 95 % A. 
General procedure 
3-Bromobenzaldehyde (200 mg, 1.08 mmol) and ACQ2 (359 mg, 1.62 mmol) were 
dissolved in dry CH2Cl2/MeOH mixture (18 mL, 1:2 v/v), anh. AcOH (93 μL, 1.62 mmol) 
was added and mixture was stirred under Ar atmosphere at room temperature. After 2 h, 
NaBH4 (245 mg, 6.48 mmol) was added and stirring at r.t. was continued for another 18 h. 
Solvents were removed under reduced pressure and the residue was dissolved in CH2Cl2 
(40 mL). The organic layer was washed with 2M NH4OH (15 mL). The layers were separated, 
and water layer was extracted with CH2Cl2 (2×15 mL). Combined organic layers were washed 
with brine and dried over anh. Na2SO4. Finally, the solvent was removed under reduced 
pressure and crude product was purified by dry-flash chromatography (SiO2: CH2Cl2/MeOH). 
N-(3-Bromobenzyl)-N'-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4) 
The crude product was purified using dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). Yield: 380 mg (90 %). Pale yellow amorphous powder. m.p. 
137-138 °C; IR (ATR, cm-1): 3314w, 3184w, 3032w, 2953s, 2896m, 2843m, 1606w, 1581s, 
1540m, 1450m, 1390w, 1364m, 1331w, 1279w, 1230w, 1200w, 1170w, 1141w, 1107w, 
1080w, 1045w, 1009w, 928w, 891w, 831w; 1H-NMR (200 MHz, CDCl3, δ / ppm): 8.53-8.48 
(1H, m), 7.96-7.92 (1H, m), 7.73-7.65 (1H, m), 7.52 (1H, s), 7.43-7.33 (2H, m), 7.26-7.13 (2H, 
m), 6.37-6.31 (1H, m), 5.84 (1H, m, -NH), 3.81 (2H, s), 3.36-3.24 (m, CH2NHCH2CH2NHAr), 
3.08-2.96 (m, CH2NHCH2CH2NHAr), 1.82 (1H, m, -NH); 13C-NMR (50 MHz, CDCl3, 
δ / ppm): 152.01, 149.78, 149.05, 142.36, 134.81, 131.02, 130.29, 130.07, 128.64, 126.63, 
125.32, 122.68, 121.22, 117.31, 99.16, 52.60, 46.70, 41.95; (+)ESI-HRMS (m/z): [M + H]+ 
390.03666 (error -0.15 ppm); Anal. Calcd. for C18H17BrClN3 × 0.5H2O: C, 54.09; H, 4.54; N, 
10.51 %. Found: C, 54.00; H, 4.34; N, 10.62 %. 
N-(3-Bromobenzyl)-N'-(7-chloroquinolin-4-yl)propane-1,3-diamine (5) 
3-Bromobenzaldehyde (200 mg, 1.08 mmol) and ACQ3 (381 mg, 1.62 mmol) were 
coupled to afford 5 (340 mg, 78 %) using AcOH (93 μL, 1.62 mmol) and NaBH4 (245 mg, 
6.48 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 5: Pale yellow amorphous powder; m.p. 70-72 °C; IR (ATR, cm-1): 
3285s, 3070m, 2944m, 2848m, 1691w, 1609w, 1579s, 1539m, 1483w, 1450m, 1364m, 1329m, 
1284w, 1248w, 1195w, 1139w, 1112w, 1076w, 988w, 903w, 857m, 823w; 1H-NMR 
(200 MHz, CDCl3, δ / ppm): 8.46 (1H, d, J = 5.4 Hz), 7.93-7.89 (1H, m), 7.55-7.31 (4H, m), 
7.30-7.17 (3H, m), 6.29 (1H, d, J = 5.4 Hz), 3.80 (2H, s), 3.44-3.32 (m, 
CH2NHCH2CH2CH2NHAr), 2.99-2.90 (m, CH2NHCH2CH2CH2NHAr), 2.11 (1H, m, -NH), 
2.01-1.87 (m, CH2NHCH2CH2CH2NHAr); 13C-NMR (50 MHz, CDCl3, δ / ppm): 151.83, 
150.43, 148.81, 141.78, 134.70, 131.28, 130.50, 130.22, 128.20, 126.94, 125.07, 122.70, 
121.88, 117.38, 98.28, 53.68, 49.11, 43.74, 27.31; (+)ESI-HRMS (m/z): [M + 2H]2+ 
202.52934 (error -2.36 ppm), [M + H]+ 404.05203 (error -0.83 ppm); Anal. Calcd. for 
4C19H19BrClN3 × 5H2O: C, 53.41; H, 5.07; N, 9.84 %. Found: C, 53.38; H, 4.73; N, 9.94 %. 
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N-(2-Bromobenzyl)-N'-(7-chloroquinolin-4-yl)propane-1,3-diamine (6) 
2-Bromobenzaldehyde (100 mg, 0.54 mmol) and ACQ3 (191 mg, 0.81 mmol) were 
coupled to afford 6 (187 mg, 85 %) using AcOH (46 μL, 0.81 mmol) and NaBH4 (123 mg, 
3.24 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 6: Yellow amorphous powder; m.p. 110-112 °C; IR (ATR, cm-1): 
3426m, 3219m, 3064w, 3009w, 2923w, 2850w, 1676w, 1610m, 1582s, 1463m, 1436m, 1383w, 
1365w, 1331w, 1308w, 1280w, 1254w, 1230w, 1200w, 1167w, 1137w, 1110w, 1080w, 1023w, 
896w, 852w, 825w, 802w; 1H-NMR (200 MHz, CDCl3, δ / ppm): 8.49-8.43 (1H, m), 7.91-7.88 
(1H, m), 7.71 (1H, m, -NH), 7.64-7.57 (1H, m), 7.47-7.32 (3H, m), 7.31-7.17 (1H, m), 
7.08-7.00 (1H, m), 6.31-6.25 (1H, m), 3.92 (2H, s), 3.45-3.34 (m, 
CH2NHCH2CH2CH2NHAr), 3.02-2.93 (m, CH2NHCH2CH2CH2NHAr), 2.26 (1H, m, -NH), 
2.03-1.88 (m, CH2NHCH2CH2CH2NHAr); 13C-NMR (50 MHz, CDCl3, δ / ppm): 151.83, 
150.52, 148.81, 138.47, 134.55, 133.10, 130.68, 129.20, 128.14, 127.69, 124.72, 124.19, 
122.21, 117.40, 98.14, 54.06, 49.12, 43.99, 27.13; (+)ESI-HRMS (m/z): [M + 2H]2+ 
202.52993 (error +0.53 ppm), [M + H]+ 404.05151 (error -2.12 ppm); Anal. Calcd. for 
C19H19BrClN3×0.5H2O: C, 55.16; H, 4.87; N, 10.16 %. Found: C, 54.97; H, 4.53; N, 10.23 % 
N-(7-Chloroquinolin-4-yl)-N'-(3,4-dibromobenzyl)ethane-1,2-diamine (7) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and ACQ2 (126 mg, 0.56 mmol) were 
coupled to afford 7 (139 mg, 78 %) using AcOH (36 μL, 0.62 mmol) and NaBH4 (84 mg, 2.22 
mmol). The crude product was purified by dry-flash chromatography (SiO2: CH2Cl2/MeOH = 
95/5). 7: Yellow amorphous powder; m.p. 136-139 °C; IR (ATR, cm-1): 3748w, 3302w, 
3074w, 2931w, 2848w, 2359w, 1611m, 1583s, 1534w, 1457w, 1371w, 1332w, 1277w, 810w; 
1H-NMR (500 MHz, CDCl3, δ / ppm): 8.51 (1H, d, J = 5.4 Hz), 7.94 (1H, d, J = 2.0 Hz), 7.67 
(1H, d, J = 9.0 Hz), 7.63 (1H, d, J = 1.9 Hz), 7.54 (1H, d, J = 8.1 Hz), 7.37 (1H, dd, J = 9.0 
Hz, J = 2.0 Hz), 7.12 (1H, dd, J = 8.1 Hz, J  = 1.9 Hz), 6.35 (1H, d, J = 5.4 Hz), 5.78 (1H, m, 
-NH), 3.78 (2H, s), 3.35-3.30 (m, CH2NHCH2CH2NHAr), 3.04-3.00 (m, 
CH2NHCH2CH2NHAr); 13C-NMR (125 MHz, CDCl3, δ / ppm): 151.92, 149.74, 148.97, 
141.06, 134.89, 133.63, 133.09, 128.65, 128.17, 125.40, 124.94, 123.21, 121.09, 117.27, 
99.19, 52.08, 46.83, 42.06; (+)ESI-HRMS (m/z): [M + H]+ = 467.94639 (error -1.78 ppm); 
Anal. Calcd. for C18H16Br2ClN3 × H2O: C, 44.34; H, 3.72; N, 8.62 %. Found: C, 44.55; H, 
3.56; N, 8.77 %. 
N-(7-Chloroquinolin-4-yl)-N'-(3,4-dibromobenzyl)propane-1,3-diamine (8) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and ACQ3 (134 mg, 0.57 mmol) were 
coupled to afford 8 (115 mg, 63 %) using AcOH (36 μL, 0.62 mmol) and NaBH4 (84 mg, 
2.22 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 8: Yellow amorphous powder; m.p. 111-113 °C; IR (ATR, cm-1): 
3269m, 2930w, 2846w, 1986w, 1610m, 1584s, 1539w, 1457w, 1369w, 1332w, 1140w, 809w; 
1H-NMR (500 MHz, CDCl3, δ / ppm): 8.50 (1H, d, J = 5.4 Hz), 7.93 (1H, d, J = 2.1 Hz), 7.61 
(1H, d, J =2.1 Hz), 7.57 (1H, d, J = 8.1 Hz), 7.51 (1H, d, J = 8.8 Hz), 7.23 (1H, dd, J =  8.8 
Hz, J = 2.1 Hz), 7.12 (1H, dd, J = 8.1 Hz, J = 2.1 Hz), 7.06 (1H, m, -NH), 6.33 (1H, d, 
J = 5.4 Hz), 3.78 (2H, s), 3.42-3.38 (m, CH2NHCH2CH2CH2NHAr), 2.94-2.90 (m, 
CH2NHCH2CH2CH2NHAr), 1.98-1.91 (m, CH2NHCH2CH2CH2NHAr), 1.78 (1H, m, -NH); 
13C-NMR (125 MHz, CDCl3, δ / ppm): 152.00, 150.23, 149.02, 140.63, 134.74, 133.77, 
133.33, 128.57, 128.44, 125.14, 125.03, 123.46, 121.54, 117.39, 98.48, 53.10, 48.91, 43.61, 
27.61; (+)ESI-HRMS (m/z): [M + H]+ = 481.96289 (error +0.02 ppm); Anal. Calcd. for 
C19H18Br2ClN3: C, 47.19; H, 3.75; N, 8.69 %. Found: C, 47.19; H, 3.80; N, 8.74 %. 
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N-(7-Chloroquinolin-4-yl)-N'-(3,4-dibromobenzyl)butane-1,4-diamine (9) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and ACQ4 (142 mg, 0.57 mmol) were 
coupled to afford 9 (130 mg, 69 %) using AcOH (36 μL, 0.62 mmol) and NaBH4 (84 mg, 
2.22 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 9: Pale yellow amorphous powder; m.p. 121-122 °C; IR (ATR, cm-1): 
3232w, 3114w, 3063w, 3012w, 2958w, 2874w, 2816w, 1612w, 1581s, 1550w, 1456m, 1430w, 
1368w, 1341w, 1320w, 1279w, 1249w, 1147w, 1014w, 896w, 871w, 850w, 815m; 1H-NMR 
(500 MHz, MeOD, δ / ppm): 8.32 (1H, d, J = 5.7 Hz), 8.05 (1H, d, J = 9.0 Hz), 7.75 (1H, d, 
J = 2.1 Hz), 7.65 (1H, d, J =2.0 Hz), 7.56 (1H, d, J = 8.2 Hz), 7.35 (1H, dd, J = 9.0 Hz, 
J = 2.1 Hz), 7.17 (1H, dd, J = 8.2 Hz, J = 2.0 Hz), 6.46 (1H, d, J = 5.7 Hz), 3.68 (2H, s), 
3.36-3.30 (m,  CH2NHCH2CH2CH2CH2NHAr), 2.63-2.58 (m, 
CH2NHCH2CH2CH2CH2NHAr), 1.80-1.72 (m, CH2NHCH2CH2CH2CH2NHAr), 1.69-1.62 
(m, CH2NHCH2CH2CH2CH2NHAr); 13C-NMR (125 MHz, MeOD, δ / ppm): 152.83, 152.49, 
149.75, 142.56, 136.42, 134.88, 134.84, 130.22, 127.70, 126.05, 125.63, 124.43, 123.99, 
118.89, 99.76, 53.26, 43.94, 28.14, 27.26; (+)ESI-HRMS (m/z): [M + 2H]2+ 248.49354 (error 
+2.55 ppm), [M + H]+ 495.97832 (error -0.43 ppm); Anal. Calcd. for C20H20Br2ClN3: C, 
48.27; H, 4.05; N, 8.44 %. Found: C, 47.94; H, 4.06; N, 8.35 %. 
N-(7-Chloroquinolin-4-yl)-N'-(3,4-dibromobenzyl)hexane-1,6-diamine (10) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and ACQ6 (158 mg, 0.57 mmol) were 
coupled to afford 10 (122 mg, 61 %) using AcOH (36 μL, 0.62 mmol) and NaBH4 (84 mg, 
2.22 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 10: Pale yellow amorphous powder; m.p. 105-106 °C; IR (ATR, 
cm-1): 3211m, 3108m, 3062m, 2933m, 2848m, 1583s, 1546m, 1490w, 1451s, 1366m, 1328w, 
1279w, 1256w, 1220w, 1200w, 1140w, 1113w, 1079w, 1010w, 900w, 884w, 850w, 832w, 
811m; 1H-NMR (500 MHz, MeOD, δ / ppm): 8.32 (1H, d, J =5.7 Hz), 8.07 (1H, d, 
J = 9.0 Hz), 7.75 (1H, d, J = 2.2 Hz), 7.65 (1H, d, J = 2.0 Hz), 7.57 (1H, d, J = 8.2 Hz), 7.36 
(1H, dd, J = 9.0 Hz, J = 2.2 Hz), 7.17 (1H, dd, J = 8.2 Hz, J = 2.0 Hz), 6.46 (1H, d, J = 5.7 
Hz) 3.65 (2H, s), 3.38-3.29 (m, CH2NH(CH2)5CH2NHAr), 2.55-2.51 (m, 
CH2NHCH2(CH2)5NHAr) 1.77-1.69 (m, CH2NH(CH2)4CH2CH2NHAr), 1.57-1.50 (m, 
CH2NHCH2CH2(CH2)4NHAr), 1.47-1.36 (m, CH2NH(CH2)2CH2CH2(CH2)2NHAr); 13C-
NMR (125 MHz, MeOD, δ / ppm): 152.85, 152.51, 149.81, 142.58, 136.39, 134.89, 134.83, 
130.23, 127.72, 126.02, 125.61, 124.43, 123.97, 118.89, 99.72, 53.29, 49.96, 44.08, 30.47, 
29.44, 28.27, 28.21; (+)ESI-HRMS (m/z): [M + 2H]2+ 262.50876 (error +0.79 ppm), [M + H]+ 
524.00906 (error -1.46 ppm); Anal. Calcd. for C22H24Br2ClN3: C, 50.26; H, 4.60; N, 7.99 %. 
Found: C, 50.07; H, 4.66; N, 8.05 %. 
N-(3,4-Dibromobenzyl)-N'-quinolin-4-ylethane-1,2-diamine (11) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and DCACQ2 (106 mg, 0.57 mmol) 
were coupled to afford 11 (120 mg, 73 %) using AcOH (112 μL, 1.94 mmol) and NaBH4 (84 
mg, 2.22 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 9/1). 11: Yellow oil; IR (ATR, cm-1): 3257m, 3065m, 2907m, 2840m, 
1581s, 1539m, 1457m, 1391w, 1336m, 1252w, 1129w, 1112w, 1013w, 809m; 1H-NMR (500 
MHz, CDCl3, δ / ppm): 8.56-8.54 (1H, m), 7.99-7.97 (1H, m), 7.78-7.76 (1H, m), 7.66-7.62 
(2H, m), 7.57-7.53 (1H, m), 7.48-7.43 (1H, m), 7.15-7.11 (1H, m), 6.41-6.39 (1H, m), 5.76 
(1H, m, -NH), 3.79 (2H, s), 3.39-3.34 (m, CH2NHCH2CH2NHAr), 3.05-3.01 (m, 
CH2NHCH2CH2NHAr), 1.85 (1H, m, -NH); 13C NMR (125 MHz, CDCl3, δ / ppm): 150.89, 
149.76, 148.24, 141.14, 133.63, 133.13, 129.75, 129.08, 128.19, 124.92, 124.77, 123.17, 
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119.45, 118.86, 98.91, 52.13, 46.98, 42.15; (+)ESI-HRMS (m/z): [M + H]+ 433.98624 (error 
+0.10 ppm); Anal. Calcd. for C18H17Br2N3: C, 49.68; H, 3.94; N, 9.66 %. Found: C, 49.29; H, 
4.00; N, 9.46 %. 
N-(3,4-Dibromobenzyl)-N'-quinolin-4-ylbutane-1,4-diamine (12) 
3,4-Dibromobenzaldehyde (100 mg, 0.38 mmol) and DCACQ4 (123 mg, 0.57 mmol) 
were coupled to afford 12 (109 mg, 63 %) using AcOH (112 μL, 1.94 mmol) and NaBH4 
(84 mg, 2.22 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 9/1). 12: Yellow oil; IR (ATR, cm-1): 3278m, 3072m, 2928m, 2856m, 
2361w, 1618w, 1581s, 1542m, 1457m, 1376w, 1341m, 1258w, 1129w, 1013w, 866w, 810m; 
1H NMR (500 MHz, CDCl3, δ / ppm): 8.54-8.52 (1H, m), 7.99-7.95 (1H, m), 7.74-7.71 (1H, 
m), 7.62-7.58 (2H, m), 7.55-7.52 (1H, m), 7.38-7.35 (1H, m), 7.12-7.10 (1H, m), 6.40-6.38 
(1H, m), 5.54 (1H, m, -NH), 3.73 (2H, s), 3.35-3.29 (m, CH2NHCH2CH2CH2CH2NHAr), 
2.72-2.66 (m, CH2NHCH2CH2CH2CH2NHAr), 1.88-1.80 (m, 
CH2NHCH2CH2CH2CH2NHAr), 1.71-1.64 (m, CH2NHCH2CH2CH2CH2NHAr); 13C NMR 
(125 MHz, CDCl3, δ / ppm): 150.82, 149.82, 148.18, 141.34, 133.53, 133.11, 129.69, 128.99, 
128.18, 124.76, 124.50, 122.92, 119.41, 118.70, 98.63, 52.70, 48.63, 43.10, 27.65, 26.41; 
(+)ESI-HRMS (m/z): [M + 2H]2+ = 231.51308 (error +3.00 ppm) [M + H]+ = 462.01695 
(error -1.19 ppm); Anal. Calcd. for C20H21Br2N3: C, 51.86; H, 4.57; N, 9.07 %. Found: C, 
52.49; H, 4.83; N, 8.73 %. 
N-(3-Bromo-4-nitrobenzyl)-N'-(7-chloroquinolin-4-yl)propane-1,3-diamine (13) 
3-Bromo-4-nitrobenzaldehyde (100 mg, 0.43 mmol) and ACQ3 (153 mg, 0.64 mmol) 
were coupled to afford 13 (127 mg, 65 %) using AcOH (37 μL, 0.65 mmol) and NaBH4 (99 
mg, 2.62 mmol). The crude product was purified by dry-flash chromatography (SiO2: 
CH2Cl2/MeOH = 95/5). 13: Yellow oil; IR (ATR, cm-1): 3431m, 2924m, 2851m, 1581s, 
1524s, 1449m, 1333s, 1280m, 1240m, 1201w, 1135m, 1078w, 1037w, 877w, 849w, 806m; 1H 
NMR (200 MHz, CDCl3, δ / ppm): 8.51-8.45 (1H, m), 7.92 (1H, d, J = 2.2 Hz), 7.81 (1H, d, 
J = 8.4 Hz), 7.72 (1H, d, J = 1.6 Hz), 7.55 (1H, d, J = 9.0 Hz), 7.39 (1H, dd, J = 8.4 Hz, 
J = 1.6 Hz), 7.24 (1H, dd, J = 9.0 Hz, J = 2.2 Hz), 6.76 (1H, m, -NH), 6.37-6.31 (1H, m), 3.89 
(2H, s), 3.47-3.35 (m, CH2NHCH2CH2CH2NHAr), 2.96-2.86 (m, 
CH2NHCH2CH2CH2NHAr), 2.15 (1H, m, -NH), 2.05-1.90 (m, CH2NHCH2CH2CH2NHAr); 
13C NMR (50 MHz, CDCl3, δ / ppm): 151.80, 150.19, 148.77, 148.56, 146.15, 134.86, 
134.37, 128.38, 127.71, 125.87, 125.18, 121.37, 117.26, 114.84, 98.59, 52.84, 48.58, 43.13, 
27.80; (+)ESI-HRMS (m/z): [M + 2H]2+ 225.02285 (error +2.18 ppm), [M + H]+ 449.03705 
(error -0.88 ppm); Anal. Calcd. for C19H18BrClN4O2 × 0.5H2O: C, 49.75; H, 4.17; N, 12.21 




















The synthesis of S1 has been previously reported.1 
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7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (S2) 
To a suspension of NaH (673 mg, 0.017 mol, 60 % dispersion in mineral oil) in dry DMF 
(20 mL) was added solution of S1 (3.82 g, 0.015 mol) in DMF (39 mL), and the mixture was 
stirred under Ar atmosphere at 100 °C. After 24 h, water was added and solvent was removed 
under reduced pressure, and crude product was purified using dry-flash chromatography 
(SiO2: CH2Cl2/MeOH). Yield 2.47 g (76 %), brown oil. IR (ATR): 3352s, 3196s, 2929w, 
2816w, 1666s, 1501m, 1450m, 1391m, 1348m, 1279w, 1188w, 1132w, 1106w, 1067w, 1001w, 
865w, 742m, 700m, 675m, 571m, 460w, cm-1. 1H NMR (500 MHz, CDCl3, δ): 7.40-7.27 (m, 
5H), 7.10–7.02 (m, 1H), 6.90–6.85 (m, 1H), 4.01 (t, J = 5.5 Hz, 2H), 3.87 (s, 2H), 3.74 (s, 
2H), 2.97–2.85 (m, 2H). 13C NMR (125 MHz, CDCl3, δ): 142.52; 136.30; 128.94; 128.61; 
127.83; 122.87; 118.58; 61.47; 49.91; 48.14; 44.95. GC/MS (m/z (%)): 213.1 ([M+], 50); 
122.0 (100); 91.0 (90). 
5,6,7,8-Tetrahydroimidazo[1,2-a]pyrazine (S3) 
In a Parr reaction bottle, S2 (2.12 g, 9.94 mmol) was dissolved in deoxygenated 
methanol (150 mL) and Pd/C (2.12 g, 10 mol% Pd) was added. The reactor was pressurized 
with 30 psi H2 and the closed system was stirred at room temperature for 5 h. The reaction 
mixture was filtered through a pad of Celite. The solvents were removed under the reduced 
pressure, and crude product was purified using dry-flash chromatography (SiO2: 
CH2Cl2/MeOH/NH3). Yield 1.07 g (88 %), brown oil. IR (ATR): 3296s, 2959s, 1660m, 
1532m, 1502s,1448m, 1369m, 1325m, 1301m, 1274m, 1199w, 1178m, 1118m, 1082m, 996w, 
961m, 936m, 896m, 853m, 741m, 693m, 671m, 528m, 467w cm-1. 1H NMR (500 MHz, 
(CD3)2SO, δ): 7.10 (s,1H), 6.89 (s, 1H), 4.10–3.90 (m, 4H), 3.30–3.10 (m, 2H). 13C NMR 
(125 MHz, CD3OD, δ): 142.44; 126.08; 118.30; 44.19; 43.13; 42.11. GC/MS (m/z (%)): 123.1 
([M+], 70); 122.1 (100). 
























a) Boc2O, CH2Cl2, 0 
oC - r.t.; b) PCC, CH2Cl2, r.t.; c) 1. Boc2O, NaOH (1M), NaHCO3, H2O, dioxane, 0 
oC - r.t. 2. KHSO4, 0 
oC;
d) ClCO2Et, Et3N, CH2Cl2, r.t.;  e) LiAlH4, THF, 0 
















tert-Butyl (3-hydroxypropyl)carbamate (S4)2 
To a solution of 3-aminopropan-1-ol (400 mg, 5.32 mmol) in CH2Cl2 (18 mL) di-tert- 
-butyl dicarbonate (1.22 g, 5.59 mmol) was added at 0 °C. The reaction was stirred at r.t. for 
2.5 h. The reaction mixture was extracted with CH2Cl2. The organic layer was washed with 
brine and dried over anhydrous Na2SO4. The organic solvent was removed under reduced 
pressure and the crude residue was purified by dry-flash chromatography (SiO2: 
hexane/EtOAc and EtOAc/MeOH) to yield S4 (913 mg, 98 %) as colorless oil. 1H NMR (500 
MHz, CDCl3, δ): 4.85 (bs, 1H), 3.85–3.50 (m, 2H), 3.40–3.20 (m, 2H), 1.75–1.62 (m, 2H), 
1.44 (s, 9H). 13C NMR (125 MHz, CDCl3, δ): 157.16; 79.58; 59.19; 36.86; 32.84; 28.32. 
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tert-Butyl (3-oxopropyl)carbamate (S5) 
Alcohol S4 (1.18 g, 6.73 mmol) was dissolved in CH2Cl2 (36 mL) followed by the 
addition of pyridinium chlorochromate (3.19 g, 14.8 mmol). After 2 h the mixture was 
transferred to a silica gel column and eluted with hexane/EtOAc to afford S5 (989 mg, 85 %) 
as a colorless oil. 
3-[(tert-Butoxycarbonyl)amino]butanoic acid (S6)3 
To a solution of 3-aminobutanoic acid (755 mg, 7.32 mmol) in dioxane/water (2:1, v/v, 
22.5 mL), 1M NaOH (aq) (3.8 mL) was added. The reaction mixture was cooled in an ice-
bath, and di-tert-butyl dicarbonate (2.396 g, 10.98 mmol) and NaHCO3 (615 mg, 7.32 mmol) 
were added. The reaction mixture was stirred for 16 h at r.t. and was then evaporated to half 
the initial volume. The residue was diluted with EtOAc, cooled in an ice-bath and acidified to 
pH 2–3 with 1M KHSO4 (aq). The layers were separated and water layer was extracted with 
EtOAc. Combined organic layers were washed with brine and dried over anh. Na2SO4. 
Finally, the solvent was removed under reduced pressure, and crude product was purified by 
dry-flash chromatography (SiO2: CH2Cl2/MeOH) to yield S6 (1.47 g, 99 %) as colorless oil. 
IR (ATR): 3330m, 2980s, 2936m, 1809m, 1715s, 1516m, 1456m, 1398m, 1370s, 1303m, 
1251m, 1213m, 1169s, 1120s, 1068m, 952w, 847m, 779w cm-1. 1H NMR (500 MHz, CDCl3, 
δ): 4.95 (bs, H-N), 4.05 (bs, 1H), 2.80–2.40 (m,2H), 1.44 (s, 9H), 1.24 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3, δ): 176.37; 155.30; 79.58; 43.32; 40.74; 28.35; 20.44. 
Ethyl 3-[(tert-butoxycarbonyl)amino]butanoate (S7) 
To a solution of S6 (1.47 g, 7.23 mmol) in dry CH2Cl2 (40 mL) Et3N (2.0 mL, 14.4 
mmol), and ClCO2Et (1.4 mL, 14.4 mL) were added. The reaction mixture was stirred for 18 h 
at r.t. and was then evaporated to dryness. The crude product was purified by dry-flash 
chromatography (SiO2: CH2Cl2/MeOH) to yield S7 (772 mg, 46 %). IR (ATR): 3365m, 
2978s, 2934m, 1714s, 1517s, 1456m, 1369s, 1299m, 1249s, 1171s, 1094m, 1058m, 1030m, 
887w, 851w, 783w, 593w cm-1. 1H NMR (500 MHz, CDCl3, δ): 4.94 (bs, H-N); 4.15 (q, J = 
7.0 Hz, 2H); 4.04 (bs, 1H); 2.60–2.30 (m, 2H); 1.44 (s, 9H); 1.26 (t, J = 7.2 Hz, 3H); 1.21 (d, 
J = 6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 171.73; 155.31; 79.47; 60.69; 43.68; 41.04; 
28.58; 20.67; 14.38. 
tert-Butyl (4-hydroxybutan-2-yl)carbamate (S8) 
To a suspension of LiAlH4 (122.7 mg, 3.235 mmol) in dry THF (3 mL) solution of S7 
(299 mg, 1.29 mmol) in dry THF (3 mL) was added at 0 °C, and the mixture was stirred for 
1 h under Ar atmosphere. The reaction mixture was diluted with THF/H2O (8 mL, 3 : 1, v/v), 
filtrated, and solvent was removed under reduced pressure. The crude product was purified 
using dry-flash chromatography (SiO2: hexane/EtOAc) to yield S8 (214 mg, 88 %) as 
colorless oil. IR (ATR): 3334m, 2974s, 2934m,1686s, 1530s, 1454m, 1390m, 1366m, 1276m, 
1250m, 1173s, 1077m, 1052m, 987w, 967w, 853w, 782w, 751w, 648w cm-1. 1H NMR 
(500 MHz, CDCl3, δ): 4.57 (bs, H-N), 3.88 (bs, 1H), 3.70–3.56 (m, 2H), 1.90–1.72 (m, 1H), 
1.45 (s, 9H), 1.40–1.30 (m, 1H), 1.19 (d, J = 6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3, 
δ): 156.71; 79.66; 58.85; 43.01; 40.61; 28.28; 21.39. 
tert-Butyl (4-oxobutan-2-yl)carbamate (S9) 
Alcohol S8 (299 mg, 1.58 mmol) was dissolved in CH2Cl2 (10 mL) followed by the 
addition of pyridinium chlorochromate (749 g, 3.47 mmol). After stirring for 2 h at r.t. the 
mixture was transferred to a silica gel column and eluted with hexane/EtOAc to afford S9 
(232 mg, 84 %) as a colorless oil. IR (ATR): 3340m, 2977s, 2933m, 2731w, 1692s, 1522s, 
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1455m, 1391m, 1368s, 1250s, 1172s, 1068m, 856w, 782w cm-1. 1H NMR (500 MHz, CDCl3, 
δ): 9.76 (s, 1H), 4.69 (bs, H-N), 4.20–4.10 (m, 1H), 2.80–2.40 (m, 2H), 1.43 (s, 9H), 1.30–













S10, R = H, 60%






S12, R = H, 70%
S13, R = CH3, 65%
16, R = H, 21%
17, R = CH3, 56%
14, R = H, 50%














a) 1. S5 or S9, AcOH, CH2Cl2/CH3OH, r.t; 2. NaBH4;  
b) TFA, CH2Cl2, r.t.; 
c) 4,7-DCQ, MW, 85  oC - 95  oC - 140  oC;
d) S14, Pd2(dba)3, SPhos, NaO










The synthesis of S144 has been previously reported. 
General procedure for reductive amination 
tert-Butyl [3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)propyl]carbamate (S10) 
Aldehyde S5 (343.2 mg, 1.981 mmol) and 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine S3 
(292.8 mg, 2.377 mmol) were dissolved in dry MeOH/CH2Cl2 mixture (24 mL, 2 : 1, v/v), 
anh. AcOH (143 µL, 2.377 mmol) was added, and the mixture was stirred under Ar 
atmosphere at rt. After 3 h, NaBH4 (450 mg, 11.9 mmol) was added, and stirring was 
continued for another 18 h at rt. Solvent was removed under reduced pressure, and the residue 
was dissolved in CH2Cl2. The organic layer was washed with 2 M NH4OH. The layers were 
separated and water layer was extracted with CH2Cl2. Combined organic layers were washed 
with brine and dried over anh. Na2SO4. Finally, the solvent was removed under reduced 
pressure, and crude product was purified by dry-flash chromatography (SiO2: hexane/EtOAc 
and CH2Cl2/MeOH). Yield 311.4 mg (60 %), colorless oil. IR (ATR): 3336w, 3112w, 3048w, 
2973m, 2934m, 2873w, 2816w, 2772w, 1700s, 1528m, 1505m, 1452m, 1390w, 1366m, 
1323w, 1275m, 1251m, 1172s, 1110m, 1077w, 994w, 943w, 858w, 734m, 698w, 676w cm-1. 
1H NMR (500 MHz, CDCl3, δ): 6.99 (s, 1H), 6.81 (s, 1H), 5.00 (bs, H-N), 4.00 (t, J = 5,5 Hz, 
2H), 3.70 (s, 2H), 3.30–3.15 (m, 2H), 2.87 (t, J = 5,3 Hz, 2H), 2.62 (t, J = 6,9 Hz, 2H), 
1.85-1.65 (m, 2H), 1.43 (s, 9H). 13C NMR (125 MHz, CDCl3, δ): 157.55; 144.33; 129.78; 
119.05; 80.66; 57.06; 53.55; 51.38; 45.55; 40.64; 29.97; 28.64. 
tert-Butyl [4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)butan-2-yl]carbamate (S11) 
Aldehyde S9 (451.7 mg, 2.41 mmol) and 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine S3 
(386.2 mg, 3.133 mmol) were coupled to afford S11 (406.2 mg, 65 %) using AcOH (188 µL, 
3.133 mmol) and NaBH4 (547 mg, 11.9 mmol). The crude product was purified by dry-flash 
chromatography (SiO2: hexane/EtOAc and CH2Cl2/MeOH). Yield 406.2 mg (65 %), colorless 
oil. The product was used for the next reactions without further purification. 
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3-(5,6-Dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)propan-1-amine (S12) 
To a solution of S10 (311.4 mg, 1.112 mmol) in CH2Cl2 (7 mL, degassed) TFA (1.3 mL) 
was added. The reaction was stirred at r.t. for 3 h. The solvent was removed under reduced 
pressure, the reaction mixture was suspended in CH2Cl2/MeOH, and NaOH (aq) was added 
until pH 10. The organic layer was washed with brine, dried (anh. Na2SO4), filtered, and 
concentrated in vacuo. Yield 139.4 mg (70 %), brown oil. IR (ATR): 3361s, 2946s, 2821s, 
1689m, 1572m, 1502s, 1469m, 1374m, 1324m, 1279m, 1199m, 1110m, 1077m, 994w, 939m, 
824w, 741m, 676m cm-1. 1H NMR (500 MHz, CD3OD, δ): 6.99 (s, 1H), 6.90 (s, 1H), 4.08-
3.98 (m, 2H), 3.66 (s, 2H), 2.97-2.85 (m, 2H), 2.77 (t, J = 7.0 Hz, 2H), 2.65 (t, J = 7.2 Hz, 
2H), 1.85-1.70 (m, 2H). 13C NMR (125 MHz, CDCl3 + CD3OD, δ): 144.25; 129.27; 119.21; 
57.02; 53.02; 51.42; 45.48; 41.42; 30.83. (+)ESI-HRMS (m/z): [M + H]+ = 181.14477 (error 
+3.04 ppm). 
4-(5,6-Dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)butan-2-amine (S13) 
To a solution of S11 (406.2 mg, 1.853 mmol) in CH2Cl2 (10 mL, degassed) and MeOH 
(0.5 mL), TFA (2 mL) was added. The reaction was stirred at r.t. for 3 h. The solvent was 
removed under reduced pressure, the reaction mixture was suspended in CH2Cl2/MeOH, and 
NaOH (aq) was added until pH 10. The organic layer was washed with brine, dried (anh. 
Na2SO4), filtered, and concentrated in vacuo. Yield 174 mg (65 %), pale-brown oil. IR 
(ATR): 3417w, 2972m, 2830m, 1677s, 1540w, 1506m, 1460w, 1424w, 1393w, 1327w, 
1280w, 1201s, 1133s, 1034w, 942w, 834w, 801w, 743w, 723w, 676w cm-1. 1H NMR (500 
MHz, (CD3)2SO, δ): 7.78 (bs, 2H, NH2), 7.14 (s, 1H), 6.97 (s, 1H), 4.05–3.95 (m, 2H), 3.75–
3.55 (m, 2H), 3.35–3.25 (m,1H), 2.90–2.75 (m, 2H), 2.70–2.55 (m, 2H), 1.90–1.55 (m, 2H), 
1.19 (d, J = 6.4 Hz, 3H). 13C NMR (125 MHz, (CD3)2SO, δ): 142.33; 126.10; 118.96; 53.07; 
50.85; 49.24; 46.01; 43.99; 31.08; 18.62. (+)ESI-HRMS (m/z): [M + H]+ = 195.16053 (error 
+2.26 ppm). 
7-Chloro-N-[3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)propyl]quinolin-4-amine (14)  
A reaction vessel containing S12 (19.1 mg, 0.105 mmol) and 4,7-dichloroquinoline 
(17.4 mg, 0.088 mmol) was stirred for 15 min at 80 °C, 30 min at 95 °C and 2 h at 140 °C in a 
MW reactor. The reaction mixture was suspended in CH2Cl2, transferred to a separation 
funnel, and washed well with 1M NaOH (aq). The organic layer was collected, dried with anh. 
Na2SO4, and  filtered. Subsequently, the solvent was removed under reduced pressure and 
product 14 was purified by dry-flash chromatography (SiO2: EtOAc/MeOH). Yield 15.1 mg 
(50 %), pale-yellow amorphous powder, mp = 71 °C. IR (ATR): 3274m, 2925s, 2853m, 
1673m, 1609m, 1582s, 1541m, 1502m, 1452m, 1370m, 1329m, 1281m, 1246w, 1202w, 
1137m, 1111m, 1080w, 942w, 900w, 879w, 850w, 809w, 767w, 731w, 677w, 647w cm-1. 1H 
NMR (500 MHz, CDCl3, δ): 8.49 (d, J = 5.2 Hz, 1H), 7.90 (s, 1H), 7.22–7.07 (m, 2H), 7.05–
6.92 (m, 2H), 6.33 (d, J = 5.2 Hz, 1H), 4.09 (t, J = 5.5 Hz, 2H), 3.88 (s, 2H), 3.50–3.42 (m, 
2H), 3.01 (t, J = 5.7 Hz, 2H), 2.95–2.85 (m, 2H), 2.10–2.00 (m, 2H). 13C NMR (125 MHz, 
CDCl3, δ): 151.88; 150.24; 148.87; 142.23; 134.56; 128.97; 128.45; 125.10; 121.23; 117.75; 
117.36; 98.44; 57.30; 51.81; 50.47; 44.01; 43.55; 24.22. (+)ESI-HRMS (m/z): [M + H]+ = 
342.14700 (error +4.53 ppm). HPLC purity, method A: tR = 3.872, area 99.36 %. Method B: 
tR = 4.504, area 99.20 %. 
7-Chloro-N-[(2R)-4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)butan-2-yl]quinolin-4- 
-amine (15) 
A reaction vessel containing S13 (63.8 mg, 0.328 mmol) and 4,7-dichloroquinoline 
(32.5 mg, 0.164 mmol) was stirred for 15 min at 80 °C, 30 min at 95 °C and 2 h at 140 °C in a 
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MW reactor. The reaction mixture was suspended in CH2Cl2, transferred to a separation 
funnel, and washed well with 1M NaOH (aq). The organic layer was collected, dried with anh. 
Na2SO4, and filtered. Subsequently, the solvent was removed under reduced pressure and 
product 15 was purified by dry-flash chromatography (SiO2: EtOAc/MeOH and 
CH2Cl2/MeOH (NH3)) and flash chromatography (Biotage SP, NH: hexane/EtOAc and 
EtOAc/MeOH). Yield 23.5 mg (40 %), pale-yellow oil. IR (ATR): 3269m, 2963m, 2818m, 
1610m, 1578s, 1538m, 1501m, 1450m, 1374m, 1329m, 1277m, 1193w, 1153w, 1110w, 
1078w, 933w, 880w, 850w, 810w, 734m, 699w, 678w, 648w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 8.47 (d, J = 5.5 Hz, 1H), 7.88 (d, J = 2.1 Hz, 1H), 7.20 (d, J = 8.9 Hz, 1H), 7.11 (s, 
1H), 7.02–6.90 (m, 3H), 6,37 (d, J = 5.5 Hz, 1H), 4.10–3.98 (m, 2H), 3.95–3.78 (m, 3H), 
3.05–2.85 (m, 3H), 2.78–2.69 (m, 1H), 2.12–2.00 (m, 1H), 1.86–1.75 (m, 1H), 1.34 (d, 
J = 6.1 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 151.88; 149.33; 149.23; 142.26; 134.53; 
128.89; 128.61; 124.92; 121.26; 117.72; 117.49; 98.71; 54.38; 51.90; 50.38; 48.00; 43.93; 
31.73; 19.28. (+)ESI-HRMS (m/z): [M + H]+ = 356.16272 (error +4.15 ppm). HPLC purity, 
method A: tR = 3.490, area 95.35 %. Method B: tR = 7.515, area 97.30 %. 
General procedure for Buchwald-Hartwig amination 
7-Chloro-N-[3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)propyl]-3-fluoroquinolin-4- 
-amine (16) 
To a flame-dried reaction tube, Pd2(dba)3 (8 mg, 0.009 mmol, 5 mol% Pd), SPhos 
(7.2 mg, 0.017 mmol) and PhMe (1.5 mL) were added. The solution was stirred at r.t. under 
an inert atmosphere for 3 min, and was then added to a mixture of S14 (53.7 mg, 
0.175 mmol), S12 (63 mg, 0.35 mmol), NaOt-Bu (47 mg, 0.49 mmol, 2.8 equiv) and PhMe 
(1.5 mL), the tube was sealed and the mixture was heated at 100 °C in an oil bath for 19 h. 
The crude product 16 was purified by dry-flash column chromatography (SiO2: hexane/EtOAc 
and EtOAc/MeOH) and furthermore by flash column chromatography (Biotage SP, NH, 
hexane/EtOAc and EtOAc/MeOH). Yield 13.4 mg (21 %), pale-yellow oil. IR (ATR): 3270s, 
2952s, 2822m, 1700m, 1597s, 1575s, 1539s, 1501s, 1455s, 1420s, 1372s, 1324m, 1298m, 
1270m, 1191m, 1139m, 1110m, 1077m, 992w, 942m, 892w, 814m, 762m, 735m, 700w, 
676w, 656w, 622w, 542w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.45 (d, J = 5.8 Hz, 
1H), 7.88 (s, 1H), 7.21 (d, J = 9.2 Hz, 1H), 7.15–7.12 (m, 1H), 6.97–6.91 (m, 2H), 4.07 (t, 
J = 5.5 Hz, 2H), 3.90–3.80 (m, 4H), 3.05–2.95 (m, 2H), 2.90–2.80 (m, 2H), 2.05–1.95 (m, 
2H). 13C NMR (125 MHz, CDCl3, δ): 146.44; 143.58 (d, J = 238.3 Hz); 142.50 (d, 
J = 27.1 Hz); 142.88; 136.67 (d, J = 5.4 Hz); 133.80; 129.05; 128.85; 125.90; 121.74 (d, 
J = 5.4 Hz); 119.15 (d, J = 5.4 Hz); 117.85; 57.61; 52.13; 50.49; 46.59; 44.01; 25.52. (+)ESI-
HRMS (m/z): [M + H]+ = 360.13767 (error +4.04 ppm). HPLC purity, method A: tR = 3.471, 
area 95.05 %. Method B: tR = 7.381, area 97.14 %. 
7-Chloro-N-[4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)butan-2-yl]-3-fluoroquinolin-4- 
-amine (17) 
Following the general procedure for Buchwald-Hartwig amination, compound 17 was 
obtained after dry-flash column chromatography (SiO2: hexane/EtOAc and EtOAc/MeOH) as 
a pale-yellow oil (31.5 mg, 56 %) from S13 (43.5 mg, 0.224 mmol) and S14 (46 mg, 
0.015 mmol) using Pd2(dba)3 (6.8 mg, 0.007 mmol), SPhos (6.1 mg, 0.015 mmol), NaOt-Bu 
(40.2 mg, 0.419 mmol) and PhMe (2 mL). IR (ATR): 3271s, 2966s, 2822m, 1596s, 1574s, 
1540m, 1502m, 1449m, 1421m, 1380s, 1350m, 1298m, 1270m, 1192m, 1142m, 1112m, 
1078m, 992w, 927w, 879w, 815w, 762w, 734m, 675w, 622w, 540w cm-1. 1H NMR 
(500 MHz, CDCl3 + CD3OD, δ): 8.42 (d, J = 5.8 Hz, 1H), 7.86 (d, J = 2.1 Hz, 1H), 7.48 (d, 
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J = 8.9 Hz, 1H), 7.10–7.00 (m, 2H), 6.93 (d, J = 1.2 Hz, 1H), 4.41–4.32 (m, 1H), 4.10–3.92 
(m, 2H), 3.87–3.75 (m, 2H), 3.10–3.00 (m, 1H), 2.99–2.89 (m, 2H), 2.80–2.70 (m, 1H), 
2.15-2.05 (m, 1H), 1.87–1.75 (m, 1H), 1.36 (d, J = 6.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3 + CD3OD, δ): 146.15; 143.05 (d, J = 239.2 Hz); 142.43; 142.12 (d, J = 28.0 Hz); 
136.38 (d, J = 4.5 Hz); 134.21; 128.26; 128.14; 125.94; 122.10 (d, J = 5.4 Hz); 119.33 (d, 
J = 4.5 Hz); 118.02; 54.23; 51.66; 50.37; 50.19; 44.05; 32.62; 21.63. (+)ESI-HRMS (m/z): 
[M + H]+ = 374.15307 (error +4,56 ppm). HPLC purity, method A: tR = 3.520, area 97.15 %. 
Method B: tR = 7.549, area 98.21 %. 
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Fig. S-1. Plots of the dose-dependent inhibit-
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